Chlorambucil in indolent chronic lymphocytic leukemia

Chlorambucil does not appear to prolong the lives of patients with early-stage chronic lymphocytic leukemia (CLL). Researchers assigned 1,535 patients with stage A CLL to daily or intermittent treatment with chlorambucil, chlorambucil and prednisone, or no treatment. Chlorambucil slowed the progression of the blood disease, but did not improve survival. Delaying treatment of CLL spares patients the side effects and complications of treatment.